Friday, September 20, 2013

Healthy Habits Linked to Longer Telomeres in Prostate Cancer

Medscape Medical News (Oncology)
Neil Osterwell
Sept. 16, 2013

A comprehensive lifestyle intervention might help prostate cancer patients live to be longer in the tooth and in the telomere, suggest results of a very small pilot study reported online in The Lancet Oncology. 
 
Among 35 men with biopsy-proven, low-risk prostate cancer who opted for active surveillance, a comprehensive lifestyle intervention including diet, activity, stress management, and support was associated with lengthening of telomeres over 5 years compared with a loss of telomere length among controls, report Dean Ornish MD, director of the Preventive Medicine Research Institute, in Sausalito, California, and colleagues.


Read the full Medscape report
(free sign-up may be required)

FDA OKs New Device to Treat BPH

Medscape Medical News
Mark Crane
Sept. 13, 2013

The US Food and Drug Administration (FDA) today authorized the marketing of the UroLift system, the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with an enlarged prostate.

The UroLift system relieves the urine flow by pulling back the prostate tissue that is pressing on the urethra.

"The UroLift provides a less invasive alternative to treating [benign prostatic hyperplasia] than surgery," Christy Foreman, director of the Office of Device Evaluation at the FDA's Center for Devices and Radiological Health, said in a release. "This device also may offer relief to men who cannot tolerate available drug therapies."

Read the full Medscape report
(Free sign-up may be required)

Complications of Robotic Surgery Underreported

Medscape Medical News
Robert Lowes
Sept 05, 2013

More injuries and deaths are linked to da Vinci robotic surgery than meet the eye, according to a new study published online August 27 in the Journal for Healthcare Quality.

As a result, "we're not learning from our performance," study coauthor Martin Makary, MD, MPH, told Medscape Medical News.

Between January 1, 2000, and August 1, 2012, the US Food and Drug Administration (FDA) received 245 adverse event (AE) reports related to the controversial da Vinci robotic surgical system, made by Intuitive Surgical. Scouring federal court records and media accounts, Dr. Makary and colleagues found 5 more cases that were never reported. They also discovered that 3 reported cases were problematic. One was submitted 930 days after the surgery, and another 292 days after. The latter case, as well as a third dubious one, was submitted to the FDA only after a media report of the patient's death appeared.

Read the full Medscape report

Wednesday, August 28, 2013

Night Work May Shift PSA Level Higher

Medscape Oncology -
Nick Mulcahy
Aug 22, 2013

Men engaged in shift work, including working at night or on a rotating schedule, had an increased likelihood of having an elevated prostate-specific antigen (PSA) value, according to new American research.

Specifically, there was a statistically significant association between current shift work and an elevated PSA of 4.0 ng/mL or greater. The study is based on data from the National Health and Nutrition Examination Survey (NHANES).

Read the full Medscape Medical News report here



Saturday, August 24, 2013

Should Men Take Finasteride to Prevent Prostate Cancer ?

A recent update to an important study analyzes whether the benefits outweigh the risks to taking finasteride to prevent prostate cancer.

Dr. Gerald Chodak discusses this subject in this new video from ProstateVideos.com.

New Prostate Screening Guidance 'Unbalanced'?

Medscape - August 16, 2013
Gerald Chodak

At the Prostate Cancer World Congress in Australia, a group of experts came up with some new recommendations regarding prostate-specific antigen (PSA) testing. This was partly in response to the US Preventive Services Task Force recommendations against routine screening. This 6-point recommendation has what Dr. Gerald Chodak thinks are a number of biased statements that potentially lead to misinformation.

Read/Watch Dr. Gerald Chodak's thoughts on this matter in this Medscape report
(Free sign-up may be required)

Friday, August 16, 2013

Metformin tied to longer prostate cancer survival

Veronica Hackethal, MD
NEW YORK | Thu Aug 15, 2013


(Reuters Health) - In older men with diabetes and prostate cancer, taking the diabetes drug metformin was linked to a lower risk of death, according to a new study.

Researchers found metformin's apparent benefits accumulated over time. Among men with diabetes in Ontario, Canada, who were over age 66, the study found a 24 percent reduction in prostate-cancer mortality for every six months of metformin use, and a similarly lower risk of death from any cause for the first six months.

"Among diabetic men with prostate cancer metformin should be considered the drug of choice, not only for diabetes control but possibly to improve prostate cancer outcomes," Dr. David Margel, a urologist at Rabin Medical Center, Petah Tikva, Israel, and lead author of the study, told Reuters Health in an email.

Read More of this Reuters Health Report